April 24, 2006

ATTN: Medical Health Officers and Branch Offices
Public Health Nursing Administrators and Assistant Administrators
Holders of Communicable Disease Control Manuals

Re: Revisions to Communicable Disease Control Manual, Chapter 2 – Immunization Program

Please note the following changes to the Communicable Disease Control Manual, Chapter 2 – Immunization Program:

Section II – Immunization Schedules
Pages 2, 6, 8 and 14:
- Correction of errors: TdaP changed to Tdap in appropriate sections;
  DTaP/IPV/Hib changed to DaPT/IPV/Hib on page 8.

Section VII – Biological Products
Page 3, Diphtheria, Acellular Pertussis, Tetanus, Polio (Quadracel™):
- Footnote specifying minimum intervals between doses in the series

Page 29, Immune Globulin Preparations or Blood: Timing Intervals For Vaccines Containing Live Measles, Mumps, Rubella, or Varicella Virus:
- New product listed: Varicella Zoster Immune Globulin (Human) VariZIG™
  Please note that the biological product page for VariZIG™ will be available at a later date.

Page 30, Immune Globulin Preparations or Blood: Timing Intervals For Vaccines Containing Live Measles, Mumps, Rubella, or Varicella Virus:
- New footnote stating that the timing consideration for anti-Rho (D) immune globulin pertains only to rubella-containing vaccines.
Page 34, Measles, Mumps, Rubella vaccine (MMR):
- Health and child care students born after 1957 are eligible for a free second dose of MMR vaccine

Pages 35, 37 and 38a, Meningococcal C conjugate vaccines:
- Men who have sex with men are included in the list of persons eligible for vaccine.

Page 41, Pneumococcal conjugate vaccine (Prevnar™); Pages 43 and 43a, Polysaccharide Pneumococcal vaccines:
- For clarity, cystic fibrosis is added to the eligibility list for these vaccines. This condition was previously included under “chronic cardiorespiratory disease.”
- “Chonic cardiorespiratory disease” is reworded to “chronic heart or lung disease.” Asthma is excluded as an indication for vaccine, unless management involves ongoing high dose oral corticosteroid therapy.

Pages 42, 43, 43a re: pneumococcal vaccines:
- New footnote: “If high risk children ≥ 2 years of age received pneumococcal polysaccharide vaccine first, offer pneumococcal conjugate vaccine at least 8 weeks after the polysaccharide vaccine.”

Page 53, Tetanus-Diphtheria-acellular Pertussis (Tdap) (Adacel™):
- New footnote “According to the National Advisory Committee on Immunization (NACI), Tdap can be administered to all those ≥ 7 years of age (there is no upper age limit for its administration). This differs from the information in the Tdap product monograph.”

Pages 63 and 65, Varicella vaccine indications:
- New eligibility groups as of April 1/06:
  - active catch-up program for susceptible children 18 to 47 months of age
  - susceptible children, adolescents, and adults at opportune health encounters

Pages 64 and 66, Varicella vaccine contraindications:
- New footnote stating that the timing consideration for anti-Rho (D) immune globulin pertains only to rubella-containing vaccines.
Page 67, Yellow Fever Vaccine:

- Under vaccine precautions, the age has been changed to $\geq 60$ years of age, to reflect a recent PHAC advisory.

Please remove and destroy the following pages from Communicable Disease Control Manual, Chapter 2 – Immunization Program:

**Section II – Immunization Schedules**

- Pages 2 and 8, Dated October 2005
- Page 6, Dated February 2006
- Page 14, Dated September 2004

**Section VII – Biological Products**

- Page 3, Dated November 2002
- Page 29, Dated August 2004
- Page 30, Dated June 2003
- Pages 34, Dated November 2005
- Pages 35, 37, 38a and 53, Dated January 2006
- Pages 41, 43, 43a, Dated October 2005
- Page 42, Dated March 2005
- Pages 63, 64, 65, 66, Dated June 2005
- Page 67, Dated December 2005

Insert the following pages in the Communicable Disease Control Manual, Chapter 2 - Immunization Program:

**Section II – Immunization Schedules**

- Pages 2, 6, 8 and 14, Dated April 2006

**Section VII – Biological Products**

- Pages 3, 29, 30, 34, 35, 37, 38a, 41, 42, 43, 43a, 53 and 63 to 67, Dated April 2006
If you have any questions or concerns, please contact Karen Pielak, Nurse Epidemiologist, or Cheryl McIntyre, Associate Nurse Epidemiologist, at telephone (604)660-6061, fax (604)660-0197 or by email at karen.pielak@bccdc.ca or cheryl.mcintyre@bccdc.ca

Sincerely,

David Patrick
Director
Epidemiology Services
BC Centre for Disease Control

DMP/kka

pc: Dr Perry Kendall          Dr. Eric Young
    Provincial Health Officer  Deputy Provincial Health Officer
    Ministry of Health Services Ministry of Health Services

Dr. Bob Fisk                     Warren O'Briain
Medical Consultant               Executive Director
Non-Communicable Disease         Comm Disease and Addiction Prevention
Ministry of Health Planning      Ministry of Health Services

Linda Poirier
Acting Manager, Communicable Disease Prevention --Immunization
Communicable Disease and Addiction Prevention
Ministry of Health Services